Details of Disease

General Information of Disease (ID: DISUR7CR)

Disease Name Venous thromboembolism
Synonyms venous thromboembolism
Disease Class BD72: Venous thromboembolism
Definition Occlusion of the lumen of a vein by a thrombus that has migrated from a distal site via the blood stream.
Disease Hierarchy
DISVS67S: Vascular disease
DISUR7CR: Venous thromboembolism
ICD Code
ICD-11
ICD-11: BD72
ICD-9
ICD-9: 453
Expand ICD-11
'BD72
Expand ICD-10
'I82; 'I82.2; 'I82.3; 'I82.8; 'I82.9
Expand ICD-9
453
Disease Identifiers
MONDO ID
MONDO_0005399
MESH ID
D054556
UMLS CUI
C1861172
MedGen ID
348285

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 7 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Ardeparin DMYRX8B Approved Small molecular drug [1]
Atorvastatin DMF28YC Approved Small molecular drug [2]
BETRIXABAN DM2C4RF Approved Small molecular drug [3]
Dicumarol DMFQCB1 Approved Small molecular drug [4]
Edoxaban tosylate DMWFM2T Approved Small molecular drug [5]
Phenprocoumon DMDO279 Approved Small molecular drug [6]
Warfarin DMJYCVW Approved Small molecular drug [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)
This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Dabigatran etexilate DMRDZ4X Phase 3 NA [8]
TB-402 DM4I6XK Phase 2 Antibody [9]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 53 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ADRA2A TTWG9A4 Limited Biomarker [10]
ANTXR2 TTOD34I Limited Biomarker [11]
F12 TTRJSMV Limited Genetic Variation [12]
F7 TTF0EGX Limited Genetic Variation [13]
F8 TT1290U Limited Genetic Variation [14]
G3BP1 TTG0R8Z Limited Biomarker [15]
KNG1 TTDJ4MY Limited Biomarker [16]
KYNU TTWQM3J Limited Altered Expression [17]
SELPLG TTS5K8U Limited Biomarker [18]
STAB2 TTM3DAY Limited Genetic Variation [19]
TNFRSF25 TTDV6BQ Limited Biomarker [20]
CHRM3 TTQ13Z5 moderate Genetic Variation [21]
FGF14 TTKJX1V moderate Genetic Variation [21]
FGG TTR31L7 moderate Genetic Variation [14]
KLKB1 TTN0PCX moderate Genetic Variation [22]
MGLL TTZ963I moderate Genetic Variation [21]
PLAT TTXAGYU moderate Biomarker [23]
ADAMTS13 TTUREBK Strong Genetic Variation [14]
APEX1 TTHGL48 Strong Genetic Variation [24]
ASRGL1 TT4WT91 Strong Genetic Variation [25]
DNM2 TTVRA5G Strong Genetic Variation [14]
ELK3 TT5OJMV Strong Biomarker [26]
EPHB1 TT8MDAC Strong Biomarker [26]
F10 TTCIHJA Strong Altered Expression [27]
F11 TTDM4ZU Strong Biomarker [28]
F9 TTFEZ5Q Strong Genetic Variation [14]
FOLH1 TT9G4N0 Strong Genetic Variation [14]
GRK5 TTTCXO0 Strong Genetic Variation [14]
ITCH TT5SEWD Strong Genetic Variation [14]
ITPR3 TTH1769 Strong Genetic Variation [29]
LPA TTU9LGY Strong Genetic Variation [30]
LTC4S TTW7OTG Strong Genetic Variation [31]
P2RY12 TTZ1DT0 Strong Genetic Variation [32]
PEPD TTLZXI0 Strong Genetic Variation [14]
PRKCH TTONI0R Strong Genetic Variation [29]
PTPRJ TTWMKXP Strong Genetic Variation [14]
SATB1 TTLFRIC Strong Genetic Variation [14]
SELP TTE5VG0 Strong Biomarker [33]
SERPINC1 TT4QPUL Strong Biomarker [34]
SERPIND1 TT8XSKJ Strong Biomarker [35]
SLC5A2 TTF8JAT Strong Biomarker [36]
SLC6A2 TTAWNKZ Strong Biomarker [26]
TFPI TT068JH Strong Altered Expression [37]
TKTL1 TTNQ1J3 Strong Biomarker [38]
TMPRSS11D TTWHYC8 Strong Genetic Variation [29]
TRPM3 TTO3TD8 Strong Genetic Variation [29]
VKORC1 TTEUC8H Strong Genetic Variation [39]
VWF TT3SZBT Strong Genetic Variation [40]
CPB2 TTP18AY Definitive Altered Expression [41]
CYP2C9 TTR40YJ Definitive Genetic Variation [42]
F13A1 TTXI2RA Definitive Genetic Variation [43]
GP6 TTTJUVZ Definitive Genetic Variation [44]
LRP1 TTF2V7I Definitive Genetic Variation [45]
------------------------------------------------------------------------------------
⏷ Show the Full List of 53 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCB9 DT68UV2 Strong Genetic Variation [14]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
KYAT1 DES9MCU Limited Genetic Variation [17]
ACSS2 DEE76VW Strong Biomarker [46]
CYP4F2 DE3GT9C Strong Biomarker [47]
MSRA DEU2ZBY Strong Genetic Variation [14]
------------------------------------------------------------------------------------
This Disease Is Related to 129 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACSM3 OT0AE1IV Limited Biomarker [48]
ADAMDEC1 OTMT7ZMG Limited Altered Expression [49]
ADGRB3 OT1EWGRW Limited Genetic Variation [19]
BLOC1S2 OTUR3E76 Limited Genetic Variation [50]
CEBPD OTNBIPMY Limited Genetic Variation [51]
CRIP3 OT7H1YOY Limited Genetic Variation [51]
CSRP3 OTECBJMV Limited Genetic Variation [51]
DNAAF3 OT3OHO0O Limited Biomarker [52]
DNAH5 OTC21RUS Limited Biomarker [52]
DNAI1 OTF6C65Q Limited Biomarker [52]
DNAJC6 OT1P6ZIE Limited Biomarker [53]
EAF2 OTSOET5L Limited Genetic Variation [14]
ERAS OT528IZO Limited Biomarker [54]
EXT1 OTRPALJK Limited Biomarker [55]
FHDC1 OTMMV8ZN Limited Biomarker [56]
FLOT2 OTZ0QR5L Limited Genetic Variation [57]
FTL OTYQA8A6 Limited Biomarker [58]
GFRA1 OT3WBVYB Limited Genetic Variation [59]
H3C1 OTGBGOZW Limited Biomarker [60]
HIRA OTON40EJ Limited Genetic Variation [61]
IMPACT OTQ923OB Limited Biomarker [62]
INF2 OT8ZM13C Limited Biomarker [56]
KYAT3 OTO4U2QK Limited Biomarker [17]
LRPAP1 OT6DVD2Q Limited Genetic Variation [63]
LY86 OTTZB64A Limited Biomarker [29]
MRPL37 OTVD0REO Limited Genetic Variation [64]
PACC1 OTKBS8CC Limited Biomarker [65]
PANX1 OTXPEDOK Limited Biomarker [66]
PCBD1 OTDSRUD5 Limited Biomarker [52]
PEAR1 OT2XLTB2 Limited Biomarker [10]
POU3F1 OTYARA94 Limited Biomarker [67]
PPL OTTM4WDO Limited Biomarker [68]
PTS OTTYWQXR Limited Biomarker [69]
RAN OT2TER5M Limited Biomarker [70]
RERE OT3G4GBZ Limited Biomarker [71]
RIMS1 OT10T7CK Limited Biomarker [72]
RPL23 OTXI1YLM Limited Biomarker [73]
RPL5 OTM8EBRI Limited Biomarker [73]
RPL9 OTKE01O8 Limited Biomarker [73]
SAGE1 OT4H6FFA Limited Biomarker [27]
SCUBE1 OT4JY1UY Limited Genetic Variation [59]
SFXN1 OTL66767 Limited Biomarker [74]
SV2C OTIH108W Limited Biomarker [75]
TMBIM4 OT8712PP Limited Genetic Variation [76]
ACAD8 OT3JI5GB Disputed Biomarker [77]
ADAM29 OTGLTTKU moderate Genetic Variation [21]
AK4 OTA0T02Q moderate Genetic Variation [21]
ARHGEF28 OT3F32IU moderate Genetic Variation [21]
B3GAT2 OTNSM9XP moderate Genetic Variation [72]
DLC1 OTP8LMCR moderate Genetic Variation [21]
EFEMP1 OTZVUOOB moderate Genetic Variation [21]
FAM228A OTCQHW47 moderate Genetic Variation [21]
FBXO15 OTJHEFE5 moderate Genetic Variation [21]
FGA OTMIHY80 moderate Genetic Variation [78]
NAALADL2 OT2HOGPQ moderate Genetic Variation [21]
NME7 OTYMBK3Q moderate Genetic Variation [14]
PAPPA2 OTXYGTUZ moderate Genetic Variation [21]
PCMTD1 OT5TS6P7 moderate Genetic Variation [21]
PLXNA4 OT5XKB3Q moderate Genetic Variation [21]
PSD OTUZIXUZ moderate Biomarker [79]
RSAD2 OTCA9WCM moderate Genetic Variation [21]
TSEN15 OT14UW31 moderate Genetic Variation [21]
A2M OTFTX90K Strong Biomarker [80]
A4GALT OTPX3UGY Strong Genetic Variation [14]
ACCS OTHIHI9D Strong Biomarker [46]
AMBRA1 OTY0YGT9 Strong Genetic Variation [14]
ANK2 OTWB4R1Y Strong Genetic Variation [14]
ARMH4 OT25GBJM Strong Genetic Variation [14]
ASPG OT5E2EKR Strong Biomarker [81]
ATP1B1 OTTO6ZP4 Strong Genetic Variation [14]
ATXN7L1 OT5EZO0M Strong Genetic Variation [14]
BLZF1 OT5QD8FG Strong Genetic Variation [22]
BRCC3 OTK0ZN7Y Strong Genetic Variation [82]
C1orf198 OTK3L4G7 Strong Genetic Variation [14]
C4BPA OTHNH6Y8 Strong Genetic Variation [14]
CACFD1 OT45BDJU Strong Genetic Variation [83]
CATSPERB OTZ0WQL2 Strong Genetic Variation [82]
CCDC181 OTPE3H8B Strong Genetic Variation [22]
CD63 OT2UGZA9 Strong Biomarker [84]
CLEC1B OTO38TRG Strong Biomarker [85]
COPZ1 OTJXGQQW Strong Genetic Variation [14]
COX7A2L OTY21FKV Strong Genetic Variation [78]
CYP4V2 OTQKNK0D Strong Genetic Variation [86]
EBF2 OTFWZE51 Strong Genetic Variation [14]
ERCC3 OTVAW3P1 Strong Genetic Variation [14]
FAM98A OTBLMZXO Strong Genetic Variation [29]
FNBP4 OTV1UBCS Strong Genetic Variation [14]
FUNDC2 OTY3TQM5 Strong Genetic Variation [14]
GBGT1 OTRB3JK7 Strong Genetic Variation [14]
GCA OTAJ7ZHG Strong Biomarker [87]
GRK4 OTUU8V2S Strong Genetic Variation [14]
HIC1 OTI9TWY4 Strong Genetic Variation [14]
IER2 OT5OY8BO Strong Genetic Variation [14]
IQGAP2 OTX2UA7P Strong Genetic Variation [29]
KBTBD4 OTXBRQFR Strong Genetic Variation [14]
KIFAP3 OT450PAO Strong Genetic Variation [14]
LEMD3 OTILAM4I Strong Genetic Variation [29]
LRP4 OTO4M459 Strong Genetic Variation [14]
MARCHF1 OTI2EYO6 Strong Biomarker [88]
MPHOSPH9 OTNUNDQN Strong Genetic Variation [14]
MTCP1 OT4O23TK Strong Genetic Variation [82]
NAV2 OTGAOL01 Strong Genetic Variation [14]
NCOA6 OTOMIGTV Strong Genetic Variation [14]
NLRP2 OTJA81JU Strong Genetic Variation [14]
NUGGC OTKQLKWO Strong Genetic Variation [14]
NUP205 OTJKHCY6 Strong Genetic Variation [29]
PAGR1 OTXR5PQ8 Strong Genetic Variation [89]
PC OT6O0V51 Strong Genetic Variation [90]
PDPN OTBUV19I Strong Biomarker [91]
PHF21A OTU3FFG4 Strong Genetic Variation [14]
PLA2G15 OT6VJTPA Strong Biomarker [46]
PLCG2 OTGVC9MY Strong Genetic Variation [14]
PLEK OTB73XXA Strong Genetic Variation [14]
PLXDC2 OTS1FUV6 Strong Genetic Variation [92]
PROS1 OTXQWNOI Strong Genetic Variation [93]
PSMC3 OTSKT0JI Strong Genetic Variation [14]
RELN OTLKMW1O Strong Genetic Variation [29]
SBNO1 OTNX3RL0 Strong Genetic Variation [14]
SMG6 OTRCEJQL Strong Genetic Variation [14]
ST3GAL4 OTNENJZQ Strong Genetic Variation [14]
STX10 OTYS3HBD Strong Genetic Variation [14]
SURF4 OTCSXJ9C Strong Genetic Variation [83]
SYT6 OTE3F36L Strong Genetic Variation [14]
TBC1D5 OTNHLLAX Strong Genetic Variation [14]
TC2N OT6482WN Strong Genetic Variation [14]
TMLHE OTH4ZLJP Strong Genetic Variation [14]
TRPC4AP OTNJ9IFS Strong Genetic Variation [14]
HABP2 OTAUIPW0 Definitive Genetic Variation [94]
PLA1A OT2IXYNX Definitive Genetic Variation [95]
------------------------------------------------------------------------------------
⏷ Show the Full List of 129 DOT(s)

References

1 Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
2 Atorvastatin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
4 Dicumarol FDA Label
5 Clinical pipeline report, company report or official report of Daiichi Sankyo.
6 Phenprocoumon FDA Label
7 Warfarin FDA Label
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 ClinicalTrials.gov (NCT00793234) Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery. U.S. National Institutes of Health.
10 Association of Genetic Variability in Selected Genes in Patients With Deep Vein Thrombosis and Platelet Hyperaggregability.Clin Appl Thromb Hemost. 2018 Oct;24(7):1027-1032. doi: 10.1177/1076029618779136. Epub 2018 Jun 4.
11 Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data.Thromb Res. 2017 Jul;155:48-52. doi: 10.1016/j.thromres.2017.04.023. Epub 2017 Apr 26.
12 The prevalence of heterozygous F12 mutations in Chinese population and its relevance to incidents of thrombosis.BMC Med Genet. 2018 Mar 27;19(1):50. doi: 10.1186/s12881-018-0557-1.
13 Factor VII coagulant activity, factor VII -670A/C and -402G/A polymorphisms, and risk of venous thromboembolism.J Thromb Haemost. 2007 Aug;5(8):1674-8. doi: 10.1111/j.1538-7836.2007.02620.x.
14 Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.Blood. 2019 Nov 7;134(19):1645-1657. doi: 10.1182/blood.2019000435.
15 A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus.Clin Proteomics. 2017 Apr 8;14:11. doi: 10.1186/s12014-017-9146-0. eCollection 2017.
16 Plasma Concentrations of High Molecular Weight Kininogen and Prekallikrein and Venous Thromboembolism Incidence in the General Population.Thromb Haemost. 2019 May;119(5):834-843. doi: 10.1055/s-0039-1678737. Epub 2019 Feb 19.
17 Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism.Thromb Res. 2018 May;165:6-13. doi: 10.1016/j.thromres.2018.03.003. Epub 2018 Mar 8.
18 Elevated plasma levels of P-selectin glycoprotein ligand-1-positive microvesicles in patients with unprovoked venous thromboembolism.J Thromb Haemost. 2018 May 31. doi: 10.1111/jth.14162. Online ahead of print.
19 A multi-stage multi-design strategy provides strong evidence that the BAI3 locus is associated with early-onset venous thromboembolism.J Thromb Haemost. 2010 Dec;8(12):2671-9. doi: 10.1111/j.1538-7836.2010.04092.x.
20 Pathologic up-regulation of TNFSF15-TNFRSF25 axis sustains endothelial dysfunction in unprovoked venous thromboembolism.Cardiovasc Res. 2020 Mar 1;116(3):698-707. doi: 10.1093/cvr/cvz131.
21 A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis.BMC Med Genet. 2013 Mar 20;14:36. doi: 10.1186/1471-2350-14-36.
22 A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q.J Thromb Haemost. 2012 Aug;10(8):1521-31. doi: 10.1111/j.1538-7836.2012.04810.x.
23 A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.J Thromb Haemost. 2017 May;15(5):961-971. doi: 10.1111/jth.13658. Epub 2017 Mar 11.
24 Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.J Thromb Thrombolysis. 2020 Feb;49(2):214-219. doi: 10.1007/s11239-019-01943-5.
25 Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.J Clin Oncol. 2018 Sep 14:JCO2018784595. doi: 10.1200/JCO.2018.78.4595. Online ahead of print.
26 Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors.Haematologica. 2020 Jan;105(1):218-225. doi: 10.3324/haematol.2019.217083. Epub 2019 May 2.
27 Venous thromboembolism chemoprophylaxis regimens in trauma and surgery patients with obesity: A systematic review.J Trauma Acute Care Surg. 2020 Apr;88(4):522-535. doi: 10.1097/TA.0000000000002538.
28 Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):103-111. doi: 10.1161/ATVBAHA.119.313503. Epub 2019 Nov 26.
29 Identification of unique venous thromboembolism-susceptibility variants in African-Americans.Thromb Haemost. 2017 Apr 3;117(4):758-768. doi: 10.1160/TH16-08-0652. Epub 2017 Feb 16.
30 Lipoprotein(a) is not associated with venous thromboembolism risk.Scand Cardiovasc J. 2019 Jun;53(3):125-132. doi: 10.1080/14017431.2019.1612087. Epub 2019 May 9.
31 Novel mutations in leukotriene C4 synthase and risk of cardiovascular disease based on genotypes from 50,000 individuals.J Thromb Haemost. 2010 Aug;8(8):1694-701. doi: 10.1111/j.1538-7836.2010.03903.x. Epub 2010 May 4.
32 Polymorphisms of platelet ADP receptor P2RY12 in the risk of venous thromboembolism in the Korean population.Clin Appl Thromb Hemost. 2012 Jul;18(4):416-20. doi: 10.1177/1076029611426283. Epub 2012 Jan 23.
33 Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.J Thromb Haemost. 2019 Nov;17(11):1912-1922. doi: 10.1111/jth.14579. Epub 2019 Aug 8.
34 Molecular basis of SERPINC1 mutations in Japanese patients with antithrombin deficiency.Thromb Res. 2019 Jun;178:159-170. doi: 10.1016/j.thromres.2019.04.004. Epub 2019 Apr 11.
35 [Recurrent venous thromboembolism caused by heparin cofactor II deficiency. A case].Presse Med. 1991 Jul 6-13;20(26):1211-4.
36 Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.Diabetes Metab Res Rev. 2020 Jan;36(1):e3174. doi: 10.1002/dmrr.3174. Epub 2019 May 27.
37 Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.Blood Cancer J. 2018 Nov 7;8(11):102. doi: 10.1038/s41408-018-0135-y.
38 A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.J Thromb Thrombolysis. 2017 Feb;43(2):252-262. doi: 10.1007/s11239-016-1433-5.
39 Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism.Pharmacogenomics J. 2018 Sep;18(5):646-651. doi: 10.1038/s41397-018-0037-1. Epub 2018 Aug 10.
40 Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.Blood Rev. 2019 May;35:43-50. doi: 10.1016/j.blre.2019.03.002. Epub 2019 Mar 3.
41 Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.J Thromb Haemost. 2016 Oct;14(10):1960-1970. doi: 10.1111/jth.13431. Epub 2016 Sep 17.
42 Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.J Thromb Haemost. 2017 Nov;15(11):2165-2175. doi: 10.1111/jth.13810. Epub 2017 Sep 25.
43 Factor XIIIA-V34L and factor XIIIB-H95R in venous thromboembolism in central Iran: protective and neutral.Blood Coagul Fibrinolysis. 2014 Jul;25(5):439-43. doi: 10.1097/MBC.0000000000000073.
44 Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism.Haematologica. 2020 Jul;105(7):e358-e360. doi: 10.3324/haematol.2019.231225. Epub 2019 Nov 7.
45 Low density lipoprotein receptor-related protein polymorphisms are not risk factors for venous thromboembolism.Thromb Res. 2008;121(5):625-9. doi: 10.1016/j.thromres.2007.08.002. Epub 2007 Sep 21.
46 Is Obesity Associated With Increased Risk of Deep Vein Thrombosis or Pulmonary Embolism After Hip and Knee Arthroplasty? A Large Database Study.Clin Orthop Relat Res. 2019 Mar;477(3):523-532. doi: 10.1097/CORR.0000000000000615.
47 Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.Trials. 2012 Dec 13;13:239. doi: 10.1186/1745-6215-13-239.
48 Low-Dose versus Therapeutic Range Intravenous Unfractionated Heparin Prophylaxis in the Treatment of Patients with Severe Aneurysmal Subarachnoid Hemorrhage After Aneurysm Occlusion.World Neurosurg. 2018 Sep;117:e705-e711. doi: 10.1016/j.wneu.2018.06.118. Epub 2018 Jun 27.
49 Association of ADAMDEC1 haplotype with high factor VIII levels in venous thromboembolism.Thromb Haemost. 2008 May;99(5):905-8. doi: 10.1160/TH08-01-0059.
50 Radiofrequency ablation with concomitant stab phlebectomy increases risk of endovenous heat-induced thrombosis.J Vasc Surg Venous Lymphat Disord. 2017 Mar;5(2):200-209. doi: 10.1016/j.jvsv.2016.10.081.
51 C-reactive protein 3' UTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism.Atherosclerosis. 2006 Oct;188(2):406-11. doi: 10.1016/j.atherosclerosis.2005.11.006. Epub 2005 Dec 13.
52 Clinical and laboratory characteristics of children with venous thromboembolism and protein C-deficiency: an observational Israeli-German cohort study.Br J Haematol. 2014 Nov;167(3):385-93. doi: 10.1111/bjh.13039. Epub 2014 Jul 18.
53 A genome-wide association study of the Protein C anticoagulant pathway.PLoS One. 2011;6(12):e29168. doi: 10.1371/journal.pone.0029168. Epub 2011 Dec 28.
54 ERAS: Safety checklists, antibiotics, and VTE prophylaxis.J Surg Oncol. 2017 Oct;116(5):601-607. doi: 10.1002/jso.24790. Epub 2017 Aug 28.
55 Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.J Med Econ. 2018 Jun;21(6):587-594. doi: 10.1080/13696998.2018.1444615. Epub 2018 Mar 16.
56 Discordance between surgical care improvement project adherence and postoperative outcomes: implications for new Joint Commission standards.J Surg Res. 2017 May 15;212:205-213. doi: 10.1016/j.jss.2017.01.006. Epub 2017 Jan 30.
57 European guidelines on perioperative venous thromboembolism prophylaxis: Surgery in the elderly.Eur J Anaesthesiol. 2018 Feb;35(2):116-122. doi: 10.1097/EJA.0000000000000705.
58 Plasma hepcidin is associated with future risk of venous thromboembolism.Blood Adv. 2018 Jun 12;2(11):1191-1197. doi: 10.1182/bloodadvances.2018018465.
59 Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism.J Thromb Haemost. 2011 Jun;9(6):1133-42. doi: 10.1111/j.1538-7836.2011.04272.x.
60 Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.J Thromb Haemost. 2018 Mar;16(3):508-518. doi: 10.1111/jth.13951. Epub 2018 Feb 7.
61 Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.Int J Hematol. 2019 Jan;109(1):79-90. doi: 10.1007/s12185-018-2540-1. Epub 2018 Oct 5.
62 Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis.Oncologist. 2013;18(12):1321-9. doi: 10.1634/theoncologist.2013-0226. Epub 2013 Nov 8.
63 Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis.Blood Coagul Fibrinolysis. 2005 Oct;16(7):465-8. doi: 10.1097/01.mbc.0000178831.45049.aa.
64 Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner.J Thromb Thrombolysis. 2018 Aug;46(2):154-165. doi: 10.1007/s11239-018-1662-x.
65 Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients.BMC Health Serv Res. 2018 Oct 1;18(1):749. doi: 10.1186/s12913-018-3557-0.
66 Selective inhibition of Panx1 channels decreases hemostasis and thrombosis in vivo.Thromb Res. 2019 Nov;183:56-62. doi: 10.1016/j.thromres.2019.09.028. Epub 2019 Oct 18.
67 Multi-institution Evaluation of Adherence to Comprehensive Postoperative VTE Chemoprophylaxis.Ann Surg. 2020 Jun;271(6):1072-1079. doi: 10.1097/SLA.0000000000003124.
68 Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.Oncologist. 2018 Nov;23(11):1372-1381. doi: 10.1634/theoncologist.2017-0530. Epub 2018 Aug 13.
69 Post thrombotic syndrome following deep vein thrombosis in paediatric patients.Phlebology. 2018 Apr;33(3):185-194. doi: 10.1177/0268355516686597. Epub 2017 Jan 25.
70 Analysis of the Association Between MicroRNA Biogenesis Gene Polymorphisms and Venous Thromboembolism in Koreans.Int J Mol Sci. 2019 Aug 1;20(15):3771. doi: 10.3390/ijms20153771.
71 Screening Feature Genes of Venous Thromboembolism with DNA Microarray.Chem Biol Drug Des. 2015 Oct;86(4):821-8. doi: 10.1111/cbdd.12557. Epub 2015 Apr 1.
72 Rare genetic variants in SMAP1, B3GAT2, and RIMS1 contribute to pediatric venous thromboembolism.Blood. 2017 Feb 9;129(6):783-790. doi: 10.1182/blood-2016-07-728840. Epub 2016 Dec 23.
73 Identification of biomarkers of venous thromboembolism by bioinformatics analyses.Medicine (Baltimore). 2018 Apr;97(14):e0152. doi: 10.1097/MD.0000000000010152.
74 Complement activation assessed by the plasma terminal complement complex and future risk of venous thromboembolism.J Thromb Haemost. 2019 Jun;17(6):934-943. doi: 10.1111/jth.14438. Epub 2019 May 13.
75 Synaptic vesicle 2C and its synaptic-related function.Clin Chim Acta. 2017 Sep;472:112-117. doi: 10.1016/j.cca.2017.07.029. Epub 2017 Jul 31.
76 Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a meta-analysis.Br J Haematol. 2008 Oct;143(2):284-7. doi: 10.1111/j.1365-2141.2008.07331.x. Epub 2008 Aug 15.
77 Elevated Venous Thromboembolism Risk Following Colectomy for IBD Is Equal to Those for Colorectal Cancer for Ninety Days After Surgery.Dis Colon Rectum. 2018 Mar;61(3):375-381. doi: 10.1097/DCR.0000000000001036.
78 Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.Hum Mol Genet. 2016 May 1;25(9):1867-74. doi: 10.1093/hmg/ddw037. Epub 2016 Feb 9.
79 Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study.Thromb Haemost. 2015 Feb;113(2):426-33. doi: 10.1160/TH14-06-0533. Epub 2014 Oct 2.
80 2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:2M Levels Are Associated with Venous Thromboembolism.Thromb Haemost. 2018 Apr;118(4):630-638. doi: 10.1055/s-0038-1629902. Epub 2018 Feb 15.
81 Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.Thromb Res. 2019 Jun;178:132-138. doi: 10.1016/j.thromres.2019.04.011. Epub 2019 Apr 11.
82 Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.Nat Genet. 2019 Nov;51(11):1574-1579. doi: 10.1038/s41588-019-0519-3. Epub 2019 Nov 1.
83 Genetics of venous thrombosis: insights from a new genome wide association study.PLoS One. 2011;6(9):e25581. doi: 10.1371/journal.pone.0025581. Epub 2011 Sep 27.
84 Prevention of venous thromboembolism after resection of primary liver cancer with low molecular weight heparin and its association with P-selectin, lysosomal granule glycoprotein, platelet activating factor and plasma D-dimer.Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4657-4662. doi: 10.26355/eurrev_201807_15525.
85 The role of podoplanin in cancer-associated thrombosis.Thromb Res. 2018 Apr;164 Suppl 1:S34-S39. doi: 10.1016/j.thromres.2018.01.020.
86 Association of the CYP4V2 polymorphism rs13146272 with venous thromboembolism in a Chinese population.Clin Exp Med. 2019 Feb;19(1):159-166. doi: 10.1007/s10238-018-0529-y. Epub 2018 Oct 1.
87 Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink.Rheumatology (Oxford). 2017 May 1;56(5):753-762. doi: 10.1093/rheumatology/kew482.
88 Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.Mayo Clin Proc. 2019 Jul;94(7):1242-1252. doi: 10.1016/j.mayocp.2018.09.022. Epub 2019 Feb 6.
89 The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism.Thromb Res. 2000 Aug 1;99(3):223-30. doi: 10.1016/s0049-3848(00)00236-x.
90 Activated protein C assays: A review.Clin Chim Acta. 2020 Mar;502:227-232. doi: 10.1016/j.cca.2019.11.005. Epub 2019 Nov 13.
91 Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells.Blood Adv. 2019 Apr 9;3(7):1092-1102. doi: 10.1182/bloodadvances.2018015966.
92 A Genome Wide Association Study on plasma FV levels identified PLXDC2 as a new modifier of the coagulation process.J Thromb Haemost. 2019 Nov;17(11):1808-1814. doi: 10.1111/jth.14562. Epub 2019 Jul 22.
93 Clinical Manifestation and Mutation Spectrum of 53 Unrelated Pedigrees with Protein S Deficiency in China.Thromb Haemost. 2019 Mar;119(3):449-460. doi: 10.1055/s-0038-1677031. Epub 2019 Jan 22.
94 Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry.Thromb Haemost. 2008 Feb;99(2):453-5. doi: 10.1160/TH07-10-0607.
95 The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans.Chest. 1999 Oct;116(4):880-6. doi: 10.1378/chest.116.4.880.